BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality.
BioVascular’s lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007.
BioVascular’s second product utilizes a novel mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.